The rollout of paediatric dolutegravir and virological outcomes among children living with HIV in Mozambique.

Autor:	Meque I; Elizabeth Glaser Pediatric AIDS Foundation, Maputo, Mozambique., Herrera N; Elizabeth Glaser Pediatric AIDS Foundation, Washington DC, United States of America., Nhangave A; Núcleo Provincial de Pesquisa de Gaza, Direcção Provincial de Saúde de Gaza, Xai-Xai, Mozambique., Mandlate D; Núcleo Provincial de Pesquisa de Inhambane, Direcção Provincial de Saúde de Inhambane, Inhambane, Mozambique., Guilaze R; Elizabeth Glaser Pediatric AIDS Foundation, Maputo, Mozambique., Tambo A; Elizabeth Glaser Pediatric AIDS Foundation, Maputo, Mozambique., Mussa A; Elizabeth Glaser Pediatric AIDS Foundation, Maputo, Mozambique., Bhatt N; Elizabeth Glaser Pediatric AIDS Foundation, Washington DC, United States of America., Gill MM; Elizabeth Glaser Pediatric AIDS Foundation, Washington DC, United States of America.
Jazyk:	angličtina
Zdroj:	Southern African journal of HIV medicine [South Afr J HIV Med] 2024 Jul 31; Vol. 25 (1), pp. 1578. Date of Electronic Publication: 2024 Jul 31 (Print Publication: 2024).
DOI:	10.4102/sajhivmed.v25i1.1578
Abstrakt:	Background: In 2022, Mozambique introduced Dolutegravir 10mg (pDTG), as part of paediatric antiretroviral therapy for children weighing < 20 kg. Understanding real-world challenges during national rollout can strengthen health systems in resource-limited settings. Objectives: We described the transition rate to, and new initiation of, pDTG, viral load suppression (VLS) post-pDTG, and factors associated with VLS among children living with HIV. Method: We conducted a retrospective cohort study involving children aged < 9 years and abstracted data from clinical sources. We used logistic regression to assess VLS and pDTG initiation predictors. Results: Of 1353 children, 1146 initiated pDTG; 196 (14.5%) had no recorded weight. Post-pDTG switch, 98.9% (950/961) of children maintained the same nucleoside reverse transcriptase inhibitor backbone. After initiating Abacavir/Lamivudine+pDTG, 834 (72.8%) children remained on the regimen, 156 (13.6%) switched off (majority to Dolutegravir 50mg), 22 (1.9%) had ≥ 2 anchor drug switches; 134 (11.7%) had no documented follow-up regimen. Factors associated with pDTG initiation or switch were younger age (adjusted odds ratio [AOR] = 0.71 [0.63-0.80]) and a recorded weight (AOR = 55.58 [33.88-91.18]). VLS among the 294 children with a viral load (VL) test after ≥ 5 months post-pDTG was 75.5% ( n = 222/294). Pre-pDTG VLS rate among treatment-experienced children was 56.5% ( n = 130/230). Factors associated with VLS were older age (AOR = 1.18 [1.03-1.34]) and previous VLS (AOR = 2.27 [1.27-4.06]). Conclusion: Most eligible children initiated pDTG per guidelines, improving post-pDTG VLS. Challenges included unexplained switches off pDTG after initiation, low VL coverage and inadequate documentation in clinic records. Competing Interests: The authors declare that they have no financial or personal relationship(s) that may have inappropriately influenced them in writing this article. (© 2024. The Authors.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu